Performance and outcome of the subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction.
CIED-related infection
lead complications
subcutaneous implantable cardioverter-defibrillator (S-ICD)
sudden cardiac death
transvenous lead extraction (TLE)
Journal
Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
23
10
2020
revised:
11
12
2020
accepted:
27
12
2020
pubmed:
31
12
2020
medline:
24
12
2021
entrez:
30
12
2020
Statut:
ppublish
Résumé
The subcutaneous cardioverter-defibrillator (S-ICD) may be a valuable option in patients after successful transvenous lead extraction (TLE) without indication for pacemaker therapy and persistent risk of sudden cardiac death. The aim of this study was to evaluate device performance, postoperative outcome, and safety in patients who received a S-ICD after TLE compared to patients who underwent de-novo S-ICD implantation. A retrospective analysis of all patients included into our institution's S-ICD database between September 2010 and May 2019 was conducted.The patients were divided in two groups, depending on whether they had received their S-ICD after TLE (n = 31) or de-novo (n = 113). The TLE group was significantly older with a mean age of 54.3 ± 15.7 versus 46.7 ± 14.4 years; p = .007. Leading S-ICD indication in the TLE group was previous infection (50%), whereas in the de-novo group the S-ICD was primarily chosen due to young patient age (74.6%). Median duration of follow-up was 527.0 versus 472.5 days, respectively; p = .576. Most common complication during follow-up was inappropriate ICD therapy (12.9% vs. 13.3%); p = 1.000. Pocket erosion/infection occurred in 3.2% versus 3.5% with no reported cases of systemic (re-)infection in either group; p = 1.000. All-cause mortality was low (6.2% vs. 2.7%) and entirely unrelated to S-ICD implantation or the device itself; p = .293. The S-ICD is a safe and effective alternative for patients after TLE with very similar results regarding device performance and postoperative outcome, when compared to patients who underwent de-novo S-ICD implantation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-257Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Raatikainen MJP, Arnar DO, Merkely B, Camm AJ, Hindricks G. Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association. Europace. 2016;18:iii1-iii79.
Greenspon AJ, Patel JD, Lau E, et al. 16-Year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States: 1993 to 2008. J Am Coll Cardiol. 2011;58:1001-1006.
Bongiorni MG, Dagres N, Estner H, Pison L, Todd D, Blomstrom-Lundqvist C. Management of malfunctioning and recalled pacemaker and defibrillator leads: results of the European Heart Rhythm Association survey. Europace. 2014;16:1674-1678.
Wazni O, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExICon study. An observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol. 2010;55:579-586.
Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38:2995-3005.
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36-44.
Brouwer T, Yilmaz D, Lindeboom R, et al. Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol. 2016;68:2047-2055.
Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and in-hospital outcomes associated with adoption of the subcutaneous implantable cardioverter defibrillator in the United States. JAMA Cardiol. 2016;1:900-911.
Atallah J, Erickson CC, Cecchin F, et al. Congenital heart disease multi-institutional study of implantable defibrillator lead performance in children and young adults results of the pediatric lead extractability and survival evaluation. Circulation. 2013;127:2393-2402.
Olsen T, Jørgensen OD, Nielsen JC, Thøgersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients : clinical data from the complete Danish device-cohort (1982 - 2018). Eur Heart J. 2019;40:1862-1869.
Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Hear Rhythm. 2016;13:157-164.
Viani S, Migliore F, Tola G, et al. Use and outcomes of subcutaneous implantable cardioverter defibrillator (ICD) after trans-venous ICD extraction: an analysis of current clinical practice and a comparison with trans-venous ICD reimplantation. Hear Rhythm. 2019;16:564-571.
Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Hear Rhythm. 2017;14:e503-e551.
Knops RE, Nordkamp LRAO, De GrootJR, Wilde AAM. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Hear Rhythm. 2013;10:1240-1243.
Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Hear Rhythm J. 2016;13:e50-e86.
Larsen JM, Hjortshøj SP, Nielsen JC, et al. Single-coil and dual-coil defibrillator leads and association with clinical outcomes in a complete Danish nationwide ICD cohort. Hear Rhythm. 2016;13:706-712.
Quast AFBE, van Dijk VF, Yap SC, et al. Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter-defibrillator cohort: long-term complications, replacements, and battery longevity. J Cardiovasc Electrophysiol. 2018;29:1010-1016.
Boersma L, Barr C, Knops R, et al. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol. 2017;70:830-841.
Knops RE, Olde Nordkamp LRA, Delnoy PPHM, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383:526-536.
Gould J, Klis M, Porter B, et al. Transvenous lead extraction in patients with cardiac resynchronization therapy devices is not associated with increased 30-day mortality. EP Eur. 2018;00:1-9. https://doi.org/10.1093/europace/euy290.
Regoli F, Bongiorni MG, Rordorf R, et al. High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices. Eur J Heart Fail. 2016;18:1270-1277.
Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767-777. https://doi.org/10.1093/europace/euv053.
Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythmia Electrophysiol. 2012;5:252-257.
Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944-953.
Afzal MR, Evenson C, Badin A, et al. Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator. Hear Rhythm. 2017;14:1436-1439.
Larbig R, Motloch LJ, Bettin M, et al. Postoperative ergometry-guided programming does not prevent T-wave oversensing and inappropriate shocks in S-ICD patients. PACE - Pacing Clin Electrophysiol. 2018;41:567-571.